DermaSensor Adds $4M Series B Extension, Opens Wefunder Round
Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.
DermaSensor, a Miami, Florida company that makes an AI-powered device for detecting skin cancer in primary care, has raised a $4 million Series B extension and opened a community investment round. The news was announced on September 9, 2026.
The extension follows the $16 million Series B DermaSensor closed in 2025 and brings total investment in the company to $48 million. Alongside institutional and strategic investors, the company opened a round on Wefunder that lets physicians, patients, and others invest $250 or more on the same terms as the extension. Just over $1 million has already come in through that channel, taking the total raised in the extension to $5 million. The company’s reasoning is that a broad base of small investors talking to their own doctors could help awareness of the device among the large and scattered population of primary care physicians.
DermaSensor also recently signed four commercial partnerships aimed at putting its FDA-cleared technology in front of more primary care, enterprise healthcare, and federal customers. An agreement with one of the largest health systems in the country, which was not named, gives tens of thousands of providers the ability to deploy the device, with two divisions already implementing it this year. A partnership with Henry Schein places DermaSensor inside the procurement channels of the world’s largest supplier to office-based practitioners. A commercial deal with MedTech MedCare adds more than 150 sales representatives across acute, post-acute, and ambulatory care, with a rollout that began in Texas. And a reseller partnership with Medical Place VA makes DermaSensor an exclusive reseller to the US Department of Veterans Affairs, whose patients experience skin cancer at three times the national rate.
The medical device uses elastic scattering spectroscopy combined with AI to give an immediate, objective risk assessment of suspicious lesions. In published studies it showed 96 percent sensitivity across melanoma, basal cell carcinoma, and squamous cell carcinoma, and cut missed skin cancer referrals by more than half.
DermaSensor began its commercial launch two years ago. The device is now used by hundreds of healthcare organizations and has scanned more than 45,000 lesions. Co-founded by CEO Cody Simmons and Maurice Ferre, the company has about 20 full-time employees plus contractors, with a few open roles including a channel partner account manager, and is targeting $100 million in annual recurring revenue by 2031. It is one of a growing group of medtech companies in Florida, where medtech ranks second only to fintech for venture activity in Miami.
Distributors and service providers selling into primary care practices and health systems can get verified contacts at newly funded healthcare companies each week through Healthcare Sales Leads.